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T-cell immunotherapy with a chimeric receptor against CD38 is
effective in eradicating chemotherapy-resistant B-cell lymphoma
cells overexpressing survivin induced by BMI-1
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The expression of BMI-1 (B lymphoma Mo-MLV insertion region 1
homolog), a member of the polycomb-group genes (PcG), is well
correlated with a poor prognosis and treatment failure among
patients with malignancies such as myelodysplastic syndrome,
chronic myeloid leukemia, acute myeloid leukemia and lym-
phoma.
1–3 Recently, we found that BMI-1 renders B-cell lymphoma
cells refractory to several anti-cancer drugs by inducing the
expression of survivin.
4 There is an urgent clinical need to ﬁnd
therapeutics to treat patients with lymphoma cells overexpressing
BMI-1 and survivin. Although in the pre-rituximab era (Rituximab,
IDEC Pharmaceuticals, San Diego, CA, USA), the long-term
remission rate for patients with diffuse large B-cell lymphoma
(DLBCL) was 50–60%, the addition of rituximab has led to an
enormous improvement in survival. As rituximab has more
signiﬁcantly improved the overall survival, event-free survival
and progression-free survival of patients with non-germinal center
B cell-type DLBCL, which have a poor prognosis, than those with
germinal center B cell-type DLBCL,
5–9 immunotherapy with an
antibody such as rituximab may function by overcoming drug-
resistant genes including Bcl-2, Bcl-6 and Bcl-xL.
10 We previously
developed T cells with a chimeric antigen receptor (CAR) against
CD38 and reported that these CD38-speciﬁc T cells effectively
eliminated B-cell lymphoma cells in vitro and in vivo.
11,12 This is
because CD38 is widely and highly expressed in B-cell lymphoma
cells (40–50% of patients with the B-cell typed),
13 especially in
AIDS-associated lymphoma cells
14 and DLBCL cells bearing
t(14;18) with aggressiveness (100% of these patients).
15
We, thus investigated whether T cells bearing an anti-CD38-CAR
exerted cytotoxicity against B-cell lymphoma cells expressing
BMI-1 and survivin. Here we report that, the CD38-speciﬁc T cells
efﬁciently eliminated chemotherapy-resistant B-lymphoma cells
overexpressing BMI-1 and survivin, and propose that T-cell
immunotherapy with CAR may be useful for treating refractory
B-cell lymphoma.
Two lymphoma cell lines (HT and RL) obtained from American
Type Culture Collection (ATCC) (Manassas, VA, USA) were cultured
in RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS) at 371C. The cells were transduced with a vesicular
stomatitis virus G glycoprotein (VSVG)-pseudotyped retrovirus
containing MSCV-BMI-1-Flag-IRES-GFP or MSCV-IRES-GFP alone
and the GFP-positive cells were sorted by FACS Aria (BD, San Jose,
CA, USA). Primary cells were obtained from the lymph node,
pleural effusion, and spleen of patients with lymphoma, and
peripheral blood cells from healthy donors, and subjected to
Ficoll-density centrifugation. Informed consent was obtained
from all of the patients and donors. Patients with B-cell
lymphoma and donors were examined as approved by the
institutional review board at Hiroshima University. The retroviral
vector construct consisting of GFP, the transmembrane domain of
CD8a, 4-1BB, CD3z and anti-CD38 scFv was made previously.
11
Brieﬂy, to generate a RD114-pseudotyped retrovirus, Lipofectamine-
Plus reagent (Invitrogen, Carlsbad, CA, USA) was used to transfect
293T cells with the retroviral vector including anti-CD38-CAR,
pEQ-PAM3(-E), and pRDF. Conditioned medium containing the
retrovirus was harvested after the transfection and stored at
–801C prior to use. Peripheral blood mononuclear cells were
stimulated for 48h with 7mg/ml PHA-M (Sigma, St Louis, MO, USA),
200IU/ml human Interleukin-2 (PeproTech, London, UK), and 10%
FCS in RPMI-1640 medium. Cells were transduced in high titer of
virus-rich conditioned medium with 4mg/ml polybrene (Sigma) in
a polypropylene tube coated with retroronectin by spinoculation
technique. An anti-CD38 antibody (CPK-H; MBL, Nagoya, Japan)
was added to protect transduced T cells from auto-lysis through
cross-linkage of the anti-CD38-CAR with intrinsic CD38, described
previously.
11 For the co-culture experiment, T cells were washed
with Phosphate buffered saline several times to eliminate
the residual antibodies in the medium. To detect surface
expression of the anti-CD38-CAR, cells were stained with a goat
anti-mouse (Fab’)2 polyclonal antibody conjugated to biotin
(Jackson ImmunoResearch, West Grove, PA, USA), followed by
streptavidin-PerCP (BD Biosciences, Franklin Lakes, NJ, USA).
Antibody staining was detected with a FACS Calibur ﬂow cyto-
meter (BD) as described.
11 The cytotoxicity of the transduced cells
was assessed by ﬂow cytometric analysis as described previ-
ously.
11 Cells harvested from the cultures were co-incubated in
anti-CD38-antibody-PerCP and anti-CD19-antibody-APC for two-
color staining. Speciﬁc cytotoxicity was evaluated by using the
formula (B-A)/B, where A is the number of CD19
þCD38
þGFP
 
cells after incubation with the anti-CD38-CAR-expressing T cells,
and B is the number of CD19
þCD38
þGFP
  cells after incubation
with vector-transduced T cells. Recovery of viable cells (%) was
evaluated by using the formula A/B.
We recently demonstrated that expression of survivin,
enhanced by BMI-1, is well correlated with drug-resistance against
etoposide (Sigma) or platinum-containing drugs such as oxalipla-
tin (Sigma) and cisplatin (Sigma).
4 We, then, examined whether
human T cells with an anti-CD38-CAR effectively kill B-cell
lymphoma cells overexpressing BMI-1 as well as survivin. Initially,
we conﬁrmed the expression of the anti-CD38-CAR on T cells,
freshly isolated from donors and retrovirally transduced (data not
shown). We previously reported that survivin expression was
enhanced by BMI-1, and conﬁrmed that both BMI-1 and survivin
were overexpressed in B-lymphoma cell lines, HT and RL cells,
transduced with BMI-1 (designated as HT-BMI-1 and RL-BMI-1,
respectively) (Figure 1a). Firstly, we evaluated whether T cells
bearing the anti-CD38-CAR eliminate chemotherapy-resistant HT-
BMI-1 cells overexpressing survivin and BMI-1. T cells expressing
the anti-CD38-CAR were co-cultured with HT-BMI-1 cells at an
effector (E):target (T) ratio of 1:2 for 3 days. As shown in Figure 1b,
the T cells effectively eliminated the retrovirally transduced
B-lymphoma cells in a time-dependent manner. Speciﬁc cytotoxi-
city in the 3-day co-culture was 95.19%±0.23% (mean±s.d.)
(n¼3) in HT cells transduced with control vector alone (mock) and
95.76%±0.05% (n¼3) in HT-BMI-1 cells. Next, we tested whether
the killing effect was dependent on the dose of the effectors.
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cells at an E:T ratio of 1:20 for 3 days. We conﬁrmed that these
CD38-speciﬁc T cells eliminated HT-BMI-1 cells in a dose-
dependent fashion (Figure 1c). Next, we examined whether T
cells with the anti-CD38-CAR kill RL-BMI-1 cells in similar
experiments. T cells bearing the anti-CD38-CAR were co-cultured
with RL cells overexpressing survivin and BMI-1 at an E:T ratio of
1:2 for 3 days. Speciﬁc cytotoxicity was 92.26%±0.19% (n¼3) in
RL-mock cells and 93.82%±0.11% (n¼3) in RL-BMI-1 cells. The
results were quite similar to those for HT-BMI cells. Representative
ﬂow cytometric data are shown in Figure 1d. These results
suggested that T cells with the anti-CD38-CAR functioned
successfully in eliminating B-lymphoma cells overexpressing
survivin and BMI-1, which are resistant to chemotherapy.
Next, we tested whether T cells with the anti-CD38-CAR
exerted cytotoxic activity against B-lymphoma cells harboring
both survivin and BMI-1. Six patients with refractory B-cell
lymphoma (DLBCL) were studied as shown in Table 1. Western
blotting revealed both BMI-1 and survivin to be expressed in all
the samples (data not shown). Intriguingly, T cells transduced
with the anti-CD38-CAR effectively eliminated B-lymphoma
cells from chemotherapy-resistant patients in the co-culturing
system in vitro. Mean speciﬁc cytotoxicity observed at an E:T
ratio of 1:2 for 3 days was over 90% (n¼4) (Table 1). These
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Figure 1. Cytotoxicity of human T cells retrovirally transduced with anti-CD38-CAR against B-lymphoma cells expressing both survivin and
BMI-1. (a) Expression of BMI-1 and survivin in HT-BMI-1 and RL-BMI-1 cells as well as parental mock-transduced cells respectively as revealed
by Western blotting. (b) T cells expressing the anti-CD38-CAR were co-cultured with HT-BMI-1 at an effector (E): target (T) ratio of 1 to 2 for 3
days. Cytotoxicity was assessed by ﬂow cytometry with the anti-CD38 antibody-PerCP. T cells bearing the anti-CD38-CAR were highly cytotoxic
to HT-BMI-1 cells in a time-dependent manner. (c) T cells with the anti-CD38-CAR were co-cultured with HT-BMI-1 at an E: T ratio of 1 to 20 for
3 days. The cytotoxic effect of the transduced T cells on HT-BMI-1 cells was dose-dependent compared with the results in Figure 1b. (d) T cells
bearing the anti-CD38-CAR were co-cultured with RL cells overexpressing survivin and BMI-1 at an E: Tratio of 1 to 2 for 3 days. Representative
results on the cytotoxicity with no effector (the upper panel), mock-transduced T cells (the middle panel) or T cells transduced with the anti-
CD38-CAR vector (the lower panel) at an E: T ratio of 1: 2 for 3 days are shown on the left (RL-mock) and right (RL-BMI-1 cells). T cells with the
anti-CD38-CAR eliminated RL-BMI-1 cells as effectively as RL-mock cells. The unpaired Students t-test was used to evaluate statistical
signiﬁcance. Asterisks indicate statistical signiﬁcance (**Po0.01).
Table 1. Characteristics of patients with DLBCL and cytotoxicity of
T cells harboring anti-CD38-CAR against DLBCL cells
Case Site Stage IPI Response to
chemotherapy
Expression
of BMI-1/
survivin
Speciﬁc
cytotoxicity
(%)
1 Spleen IV A 3 CR  /  91.21±2.42
2 LN III A 2 CR  /  92.31±0.78
3 LN III A 3 CR  /  94.77±0.78
4L N I V B 4 P D þ/þ 96.47±2.02
5L N I V B 3 P D þ/þ 94.30±1.53
6P E I V B 5 P D þ/þ 98.61±0.26
Abbreviations: DLBCL, diffuse large B-cell lymphoma; LN, lymph node;
PE, pleural effusion; IPI, international prognostic index. Results are
the mean±s.d. for four experiments. CR denotes complete response.
PD denotes progressive disease.
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Blood Cancer Journal & 2012 Macmillan Publishers Limitedresults showed that CD38-speciﬁc T cells efﬁciently eliminated
B-lymphoma cells with BMI-1 and survivin.
Overexpression of anti-apoptotic genes including the Bcl-2,
Bcl-x, XIAP and survivin genes is one mechanism by which cancer
cells become refractory to anti-cancer drugs. We conﬁrmed that
HT cells transduced with BMI-1 strongly expressed Bcl-x, XIAP
and survivin (data not shown). Alternatively, RL cells with BMI-1
expressed Bcl-2, Bcl-x, XIAP and survivin (data not shown).
Although we previously showed RL-BMI-1 cells were more
resistant to etoposide and platinum-containing anti-cancer drugs
like oxaliplatin and cisplatin than HT-BMI-1 cells,
4 CD38-speciﬁc
T cells exerted a similar cytotoxic effect on HT-BMI-1 and RL-BMI-1,
indicating that these autologous T cells bearing the anti-CD38-CAR
eliminated B-lymphoma cells even though the cells expressed
multiple antiapoptotic genes. Recent publications showed that
genetically-engineered T cells reactive to CD19 exerted persistent
cytotoxic effects in patients with refractory chronic lymphoid
leukemia.
16,17 These results suggest immunotherapy with T cells
bearing a CAR to be an important option in treating refractory
hematological malignancies.
In this study, we demonstrated that T cells bearing the anti-
CD38-CAR were highly cytotoxic to B-cell lymphoma cells
expressing BMI-1 and survivin. If autologous T-cell immunotherapy
using the anti-CD38-CAR is harnessed more efﬁciently for the
treatment of lymphoma, it might shed new light on a therapeutic
strategy for patients with refractory B-lymphoma cells with even
multiple anti-apoptotic gene expression.
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